search
Back to results

Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation in Patients With Diabetes Mellitus (CUT-DRESS). (CUT-DRESS)

Primary Purpose

Diabetes Mellitus, Coronary Artery Disease, Percutaneous Coronary Intervention

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Predilation with cutting balloon.
Predilation with conventional balloon
Sponsored by
Hospital Universitario La Fe
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diabetic patients Symptomatic coronary artery disease or evidence of ischemia in the presence of one or more coronary artery stenoses >50% in a native coronary artery. Exclusion Criteria: Cardiogenic shock Patients presenting with ST-segment elevation myocardial infarction Patients undergoing chronic total occlusions PCI Patients undergoing left main PCI Patients undergoing venous bypass graft lesions PCI Patients with in-stent restenosis Inability to provide informed consent Life expectancy <1year due to non-cardiac disease Currently participating in another trial before reaching first endpoint There will be no exclusion based on mode of co-morbidities, left ventricular function, number of diseased vessels and lesions, or number of target lesions.

Sites / Locations

  • Hospital de la Santa Creu i Sant Pau
  • Hospital Universitario y Politécnico La FeRecruiting
  • Hospital General de Valencia

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Study group

Control group

Arm Description

Pre-dilation with cutting balloon followed by ASES implantation.

Pre-dilation with a standard balloon (semi-compliant or non-compliant) followed by ASES implantation.

Outcomes

Primary Outcome Measures

Minimum stent area post-stenting measured by optimal coherence tomography (OCT)

Secondary Outcome Measures

Percentage of neointimal hyperplasia (%) measured by OCT coherence tomography (OCT).
Key secondary
Mean stent area measured by optimal coherence tomography
Acute procedural success
Coronary disection
Malapposition (Major/minor) post-stenting measured by optimal coherence tomography
Mean neointimal hyperplasia area measured by optimal coherence tomography
Minimum stent eccentricity measured by optimal coherence tomography
Stent asymmetry index measured by optimal coherence tomography
All cause death
Death from cardiovascular causes
Target vessel myocardial infarction
Target lesion revascularization
Stent thrombosis
Any myocardial infarction

Full Information

First Posted
March 11, 2023
Last Updated
March 23, 2023
Sponsor
Hospital Universitario La Fe
search

1. Study Identification

Unique Protocol Identification Number
NCT05801003
Brief Title
Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation in Patients With Diabetes Mellitus (CUT-DRESS).
Acronym
CUT-DRESS
Official Title
Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation in Patients With Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2023 (Actual)
Primary Completion Date
April 1, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Universitario La Fe

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Diabetes mellitus is one of the most important diseases worldwide. Patients with diabetes mellitus, as compared to those without, present a more diffuse, progressive coronary artery disease with smaller lumen dimensions leading to suboptimal outcomes after PCI and increased risk of restenosis and adverse cardiac events. Lesion pre-dilation prior to DES implantation is a crucial procedural step as it creates microdissections, which are required for optimal uptake of the drug. However, the best pre-dilation strategy has not yet been determined. Therefore, the aim of this study is to evaluate a strategy based on pre-dilation with cutting balloon (CB) followed by Abluminus Sirolimus-eluting stent (ASES) implantation for de novo coronary lesions in patients at high risk of restenosis.
Detailed Description
The study will be a prospective, multicenter, randomized controlled trial in patients with diabetes mellitus undergoing PCI with the novo coronary disease. A total of 96 diabetic patients with de novo coronary artery stenosis will be included. After being informed about the study and the potential risks, all patients meeting all the inclusion criteria and none of exclusion criteria will give written informed consent. Random allocation in a 1:1 fashion to one of the following strategies: A) Study group: Pre-dilation with cutting balloon followed by ASES implantation. B) Control group: Pre-dilation with a standard balloon (semi-compliant or non-compliant) followed by ASES implantation. Stent optimisation will be performed based on intracoronary imaging findings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Coronary Artery Disease, Percutaneous Coronary Intervention, Cutting Balloon

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, multicenter, randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
96 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study group
Arm Type
Experimental
Arm Description
Pre-dilation with cutting balloon followed by ASES implantation.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Pre-dilation with a standard balloon (semi-compliant or non-compliant) followed by ASES implantation.
Intervention Type
Device
Intervention Name(s)
Predilation with cutting balloon.
Other Intervention Name(s)
Wolverine Cutting balloon
Intervention Description
PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
Intervention Type
Device
Intervention Name(s)
Predilation with conventional balloon
Intervention Description
PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
Primary Outcome Measure Information:
Title
Minimum stent area post-stenting measured by optimal coherence tomography (OCT)
Time Frame
Immediately after the procedure
Secondary Outcome Measure Information:
Title
Percentage of neointimal hyperplasia (%) measured by OCT coherence tomography (OCT).
Description
Key secondary
Time Frame
9 month follow-up.
Title
Mean stent area measured by optimal coherence tomography
Time Frame
9 month follow-up.
Title
Acute procedural success
Time Frame
Immediately after the procedure
Title
Coronary disection
Time Frame
Immediately after the procedure
Title
Malapposition (Major/minor) post-stenting measured by optimal coherence tomography
Time Frame
Immediately after the procedure and at 9 month follow-up
Title
Mean neointimal hyperplasia area measured by optimal coherence tomography
Time Frame
9 months
Title
Minimum stent eccentricity measured by optimal coherence tomography
Time Frame
9 months
Title
Stent asymmetry index measured by optimal coherence tomography
Time Frame
9 months
Title
All cause death
Time Frame
12 months
Title
Death from cardiovascular causes
Time Frame
12 months
Title
Target vessel myocardial infarction
Time Frame
12 months
Title
Target lesion revascularization
Time Frame
12 months
Title
Stent thrombosis
Time Frame
12 months
Title
Any myocardial infarction
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diabetic patients Symptomatic coronary artery disease or evidence of ischemia in the presence of one or more coronary artery stenoses >50% in a native coronary artery. Exclusion Criteria: Cardiogenic shock Patients presenting with ST-segment elevation myocardial infarction Patients undergoing chronic total occlusions PCI Patients undergoing left main PCI Patients undergoing venous bypass graft lesions PCI Patients with in-stent restenosis Inability to provide informed consent Life expectancy <1year due to non-cardiac disease Currently participating in another trial before reaching first endpoint There will be no exclusion based on mode of co-morbidities, left ventricular function, number of diseased vessels and lesions, or number of target lesions.
Facility Information:
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Estefania Fernandez Peregrina
Facility Name
Hospital Universitario y Politécnico La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorge Sanz Sanchez, MD, PhD
Phone
440087
Email
sjorge4@gmx.com
First Name & Middle Initial & Last Name & Degree
Jose Luis Diez Gil, MD, PhD
Facility Name
Hospital General de Valencia
City
Valencia
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Rumiz González, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation in Patients With Diabetes Mellitus (CUT-DRESS).

We'll reach out to this number within 24 hrs